Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.36 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.36 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.36 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.36 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.36 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.36 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.36 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.36 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23714916 | 1.00 | ALDH1A1 (0.36) | ALDH1A1GAAHDAC3HDAC4HDAC1 | |
| SCHEMBL15197949 | 0.99 | ALDH1A1 (0.34) | ALDH1A1GAAHDAC3HDAC4HDAC1 | |
| SCHEMBL12458172 | 0.94 | ALDH1A1 (0.34) | ALDH1A1HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL19236806 | 0.89 | ALDH1A1 (0.35) | ALDH1A1GAAHDAC3HDAC4HDAC1 | |
| SCHEMBL278538 | 0.88 | POLB (0.34) | ALDH1A1GAAHDAC3HDAC4HDAC1 | |
| SCHEMBL19903913 | 0.88 | CYP19A1 (0.36) | ALDH1A1GAAHDAC3HDAC4HDAC1 | |
| SCHEMBL24084154 | 0.88 | CYP19A1 (0.36) | ALDH1A1GAAHDAC3HDAC4HDAC1 | |
| SCHEMBL19698844 | 0.87 | CYP19A1 (0.39) | ALDH1A1GAAHDAC3HDAC4HDAC1 | |
| SCHEMBL3018585 | 0.87 | PAOX (0.43) | ALDH1A1GAAHDAC3HDAC4HDAC1 | |
| SCHEMBL21480708 | 0.86 | ALDH1A1 (0.33) | ALDH1A1GAAHDAC3HDAC4HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 556 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12029736-B2 | Camptothecin derivatives and conjugates thereof | MEDIBOSTON LIMITED (HK) | 2024-07-09 | — | — | US | disclosed |
| US-12029736-B2 | Camptothecin derivatives and conjugates thereof | MEDIBOSTON LIMITED (HK) | 2024-07-09 | — | — | US | disclosed |
| US-20240218011-A1 | GLUCOCORTICOID RECEPTOR AGONISTS AND CONJUGATES THEREOF | FIREFLY BIO, INC. | 2024-07-04 | — | — | US | disclosed |
| US-12016842-B2 | Methods of using anti-CD79b immunoconjugates | GENENTECH, INC. (US) | 2024-06-25 | — | — | US | disclosed |
| US-12016842-B2 | Methods of using anti-CD79b immunoconjugates | GENENTECH, INC. (US) | 2024-06-25 | — | — | US | disclosed |
| US-20240067709-A1 | Methods and Compositions for Targeting Polyubiquitin | GENENTECH, INC. (US) | 2024-02-29 | — | — | US | disclosed |
| US-20240067709-A1 | Methods and Compositions for Targeting Polyubiquitin | GENENTECH, INC. (US) | 2024-02-29 | — | — | US | disclosed |
| US-20240066138-A1 | ANTIBODY-DRUG CONJUGATES, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | SHANGHAI RUOTUO BIOSCIENCES CO LTD (CN) | 2024-02-29 | — | — | US | disclosed |
| US-20240066138-A1 | ANTIBODY-DRUG CONJUGATES, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | SHANGHAI RUOTUO BIOSCIENCES CO LTD (CN) | 2024-02-29 | — | — | US | disclosed |
| US-20240024499-A1 | GPC3 BINDING AGENTS, CONJUGATES THEREOF AND METHODS OF USING THE SAME | ARDEAGEN CORP (US) | 2024-01-25 | — | — | US | disclosed |
| US-20080213289-A1 | Monoclonal antibody-cytotoxic drug conjugate for use in targeting and treatment of hodgkin's disease | SEATTLE GENETICS, INC. (US) | 2008-09-04 | — | — | US | disclosed |
| US-7375078-B2 | Heterocyclic self-immolative linkers and conjugates | GENENTECH, INC. (US) | 2008-05-20 | — | — | US | disclosed |
| US-20080057066-A1 | METHODS AND COMPOSITIONS FOR TARGETING RELT | GENENTECH, INC. | 2008-03-06 | — | — | US | disclosed |
| US-20080050310-A1 | ANTIBODIES AND IMMUNOCONJUGATES AND USES THEREFOR | GENENTECH, INC. (US) | 2008-02-28 | — | — | US | disclosed |
| US-20080025989-A1 | ANTI-CD70 ANTIBODY-DRUG CONJUGATES AND THEIR USE FOR THE TREATMENT OF CANCER AND IMMUNE DISORDERS | SEATTLE GENETICS, INC. (US) | 2008-01-31 | — | — | US | disclosed |
| US-20070258987-A1 | Using antibody-drug conjugate specific for CD30 as therapeutic treatment for hodgkin's disease | SEATTLE GENETICS, INC. | 2007-11-08 | — | — | US | disclosed |
| US-20070218069-A1 | antibodies that specifically binds ubiquitin comprising a lysine linkage between a lysine residue of one ubiquitin molecule and the C-terminal glycine residue of another ubiquitin molecule | GENENTECH, INC. | 2007-09-20 | — | — | US | disclosed |
| US-20070134243-A1 | Antibody drug conjugates and methods | GENENTECH, INC. | 2007-06-14 | — | — | US | disclosed |
| US-20070092940-A1 | A free cysteine amino acid is a cysteine residue which has been engineered into the parent antibody and is not part of a disulfide bridge; diagnostics and therapeutics; killing or inhibiting the proliferation of tumor cells or cancer cells | GENENTECH, INC. (US) | 2007-04-26 | — | — | US | disclosed |
| US-20070081995-A1 | Methods and compositions for targeting IFNAR2 | GENENTECH, INC. | 2007-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12016842-B2 | Methods of using anti-CD79b immunoconjugates | CD79B, CD99, BCL6 | ALDH1A1 2981/4885GAA 1640/4885HDAC3 1686/4885 |
| US-20070081995-A1 | Methods and compositions for targeting IFNAR2 | IFNAR1, IFNG, EIF2AK2 | ALDH1A1 4868/4885GAA 1197/4885HDAC3 2291/4885 |
| US-20080213289-A1 | Monoclonal antibody-cytotoxic drug conjugate for use in targeting and treatment of hodgkin's disease | HCFC1, PHF20, H1-10 | ALDH1A1 1886/4885GAA 3375/4885HDAC3 1899/4885 |
| US-20080025989-A1 | ANTI-CD70 ANTIBODY-DRUG CONJUGATES AND THEIR USE FOR THE TREATMENT OF CANCER AND IMMUNE DISORDERS | CD74, CD63, CD2 | ALDH1A1 1067/4885GAA 535/4885HDAC3 3371/4885 |
| US-20240218011-A1 | GLUCOCORTICOID RECEPTOR AGONISTS AND CONJUGATES THEREOF | NR3C1, NR3C2, MC2R | ALDH1A1 3778/4885GAA 2646/4885HDAC3 1371/4885 |
| US-20070218069-A1 | antibodies that specifically binds ubiquitin comprising a lysine linkage between a lysine residue of one ubiquitin molecule and the C-terminal glycine residue of another ubiquitin molecule | STUB1, UBQLN1, UBAP2 | ALDH1A1 3778/4885GAA 1593/4885HDAC3 3240/4885 |
| US-12029736-B2 | Camptothecin derivatives and conjugates thereof | TOP2A, TOP1, XPA | ALDH1A1 1163/4885GAA 1021/4885HDAC3 4099/4885 |
| US-20070258987-A1 | Using antibody-drug conjugate specific for CD30 as therapeutic treatment for hodgkin's disease | HCFC1, PHF20, H1-10 | ALDH1A1 1554/4885GAA 3446/4885HDAC3 1790/4885 |
| US-20080057066-A1 | METHODS AND COMPOSITIONS FOR TARGETING RELT | REL, FCGRT, IL6ST | ALDH1A1 4724/4885GAA 3014/4885HDAC3 732/4885 |
| US-20080050310-A1 | ANTIBODIES AND IMMUNOCONJUGATES AND USES THEREFOR | CD22, CD2BP2, CD2 | ALDH1A1 404/4885GAA 590/4885HDAC3 3910/4885 |
| US-20240067709-A1 | Methods and Compositions for Targeting Polyubiquitin | PSMG3, STUB1, USP47 | ALDH1A1 4718/4885GAA 1533/4885HDAC3 1656/4885 |
| US-20240024499-A1 | GPC3 BINDING AGENTS, CONJUGATES THEREOF AND METHODS OF USING THE SAME | LGALS3BP, LGALS3, B3GAT3 | ALDH1A1 2684/4885GAA 881/4885HDAC3 1008/4885 |
| US-20070134243-A1 | Antibody drug conjugates and methods | BOD1L1, MKI67, CCNI | ALDH1A1 115/4885GAA 288/4885HDAC3 3690/4885 |
| US-20240066138-A1 | ANTIBODY-DRUG CONJUGATES, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | FCGR1A, FCGRT, FCGR2A | ALDH1A1 315/4885GAA 51/4885HDAC3 1896/4885 |
| US-20070092940-A1 | A free cysteine amino acid is a cysteine residue which has been engineered into the parent antibody and is not part of a disulfide bridge; diagnostics and therapeutics; killing or inhibiting the proliferation of tumor cells or cancer cells | LNPEP, CSTB, ALB | ALDH1A1 771/4885GAA 4132/4885HDAC3 4702/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.